Medicament for treating neurasthenia and preparation method thereof

Abstract

The invention relates to the technical field of neurology, in particular to a medicine for treating neurasthenia, which comprises the following components (by mass percentage): trimetazine: 2-4%, midecamycin: 1-5%, teabutemetone : 30-40%, Taurine: 15-17%, Ketotifen: 2-6%, Catechin: 23-25%, Niacinamide: 3-5%, Oleanolic acid: 1-3% , Quetiapine: 1.5-2.5%, Loxoprofen: 2.5-11.5%. The invention also discloses a preparation method of the drug, which includes the following steps: step 1: preparing materials, step 2: drying and grinding into powder, step 3: pulverizing, step 4: preparing ethanol solution, step 5: concentrating and drying, and step 6 : extract medicine. The invention can effectively improve body function and immunity, has significant curative effect on treating neurasthenia, has no toxic and side effects on human body, can relieve anxiety and cognitive deficiency symptoms, and has the effects of clearing away heat and fire, regulating qi and dredging collaterals.

Description

technical field [0001] The invention relates to the technical field of neurology, in particular to a medicine for treating neurasthenia and a preparation method thereof. Background technique [0002] Neurasthenia is a relatively broad term, and currently usually includes some depression, anxiety disorders, tension headaches, insomnia, indigestion, etc. Neurasthenia refers to the phenomenon of mental excitability and mental fatigue due to long-term tension and pressure, often accompanied by emotional troubles, irritability, sleep disturbance, muscle tension pain, etc. These symptoms cannot be attributed to brain, physical diseases or other diseases. Mental diseases, symptoms are mild and severe, fluctuations are related to psychosocial factors, and the course of the disease is often protracted. [0003] In terms of treatment, modern medicine advocates the use of psychotherapy on the one hand, and chemical drug treatment on the other hand. Chemical drugs have only symptomatic...

AI Technical Summary

Problems solved by technology

[0003] In terms of treatment, modern medicine advocates the use of psychotherapy on the one hand, and chemical drug treatment on the other hand. Chemical drugs have only symptomatic therapeutic effects on neurasthenia. At present, the most used anti-anxiety agents, such as tranquilizers, can improve neurological symptoms. It weakens the patient's mood, relaxes muscles, and calms and hypnotizes the patient. Therefore, it is effective for the patient's psychological and physical symptoms. However, only short-term use of anti-anxiety agents has a better effect. Long-term use not only has poor curative effect, but also easily causes drug dependence. , while neurasthenia is protracted, short-term chemical drug symptomatic treatment cannot fundamentally solve the problem